Virtual Reality Intervention Alleviates Dyspnea in Patients Recovering From COVID Pneumonia
Primary Purpose
Covid19, Dyspnea
Status
Completed
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
COVVR_Synch
COVVR_Asynch
Sponsored by
About this trial
This is an interventional supportive care trial for Covid19
Eligibility Criteria
Inclusion Criteria:
- Recovering from COVID-19 pneumonia confirmed by RT-PCR for SARS-CoV-2
- Presented with persistent dyspnea with a self-rated intensity of five or higher (out of ten) on a visual analog dyspnea scale. ( "Do you have difficulty breathing?" "On a scale of 0 to 10, with 0 being no difficulty to breathe and 10 being the worst difficulty to breathe that you can imagine, where do you rank?".) This dyspnea rating will only used as an inclusion criterion and not as an outcome.
- Being able to give consent
- Being able to understand and speak French or English
Exclusion Criteria:
- Any unstable respiratory, neurological, and cardiac conditions
- Any psychiatric illness
- Montreal Cognitive Assessment (MoCA) score below 25.
Sites / Locations
- Hopitaux Universitaires de Geneve (HUG)
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
COVVR_A
COVVR_B
Arm Description
Participants in the COVVR_A arm complete the synchronous block first, followed by the asynchronous block.
Participants in the COVVR_B arm complete the asynchronous block first, followed by the synchronous block.
Outcomes
Primary Outcome Measures
Efficacy (Breathing Comfort & Discomfort)
Efficacy will be evaluated based on subjective feedback by the patients regarding their breathing comfort and discomfort, depending on the intervention.
Subjective ratings will be measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree.
Comfort item: "My breathing was enjoyable" Discomfort item: "I had difficulty breathing"
VR Intervention Feasibility
Feasibility will be evaluated using a feedback questionnaire, alongside open feedback. Agreement with the questionnaire items indicates better feasibility, acceptance, and perceived outcome.
Ratings will be measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree.
Satisfaction: Did you enjoy the VR experience? Rehabilitation: Would you like to continue using the device during your recovery? Hospital Use: Would you have liked to use this earlier during your stay at the hospital? Home Use: Would you like to continue using the device at home? Respiratory benefit: Do you think the VR feedback improved your breathing? Well-being benefit: Did the VR feedback make you feel better?
Secondary Outcome Measures
Embodiment
Change in subjective ratings about embodiment depending on VR intervention. Two control items are included that are not expected to change between conditions.
Ratings will be measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree.
Breathing awareness: It seemed as if the flashing was my respiration Control 1: It seemed as if I had three bodies Breathing agency: I felt as if the virtual body was breathing with me Control 2: I felt as if the virtual body was drifting with the flashing
Respiratory Rate
Change in respiratory rate depending on VR intervention. Respiratory rate (RR) will be measured in breaths per minute. RR will be assessed with respect to baseline recordings.
Respiratory Rate Variability
Change in respiratory rate variability depending on VR intervention. Respiratory rate variability (RRV) will be measured using inter-breath intervals (IBI).
RRV will be assessed with respect to baseline recordings.
Full Information
NCT ID
NCT04844567
First Posted
March 18, 2021
Last Updated
March 1, 2022
Sponsor
Ecole Polytechnique Fédérale de Lausanne
Collaborators
Mindmaze SA
1. Study Identification
Unique Protocol Identification Number
NCT04844567
Brief Title
Virtual Reality Intervention Alleviates Dyspnea in Patients Recovering From COVID Pneumonia
Official Title
Virtual Reality Intervention Alleviates Dyspnea in Patients Recovering From COVID Pneumonia
Study Type
Interventional
2. Study Status
Record Verification Date
March 2022
Overall Recruitment Status
Completed
Study Start Date
November 26, 2020 (Actual)
Primary Completion Date
April 6, 2021 (Actual)
Study Completion Date
April 6, 2021 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ecole Polytechnique Fédérale de Lausanne
Collaborators
Mindmaze SA
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The present COVID-19 Virtual Reality (COVVR) clinical study is performed to test the hypothesis that an immersive virtual reality (iVR)-based Digital Therapeutics (DTx), would alleviate dyspnea by improving breathing comfort in patients recovering from COVID-19 pneumonia presenting with persistent dyspnea. We will further evaluate participants' perceived awareness of and agency over their breathing movements. Finally, we will track patients' perceived benefits related to the iVR intervention and the feasibility of using COVVR in the clinic or at home.
Detailed Description
Persistent dyspnea is the experience of breathlessness that persists despite optimal treatment of the underlying pathophysiology, and results in physical, psychosocial disability for the patient. As observed for SARS-CoV and MERS-CoV patients, a significant portion of COVID-19 patients present with persistent respiratory physiological impairment and persistent breathlessness that may not be addressed with conventional respiratory treatment such as oxygen, bronchodilators, diuretics or non-invasive ventilation.
Previous research on respiration-related feedback in Virtual Reality (VR) has demonstrated strong and replicable effects of VR feedback over one's perceived sense of agency and control over one's virtually embodied respiration. Based on these studies, the VR intervention evaluated here aims to alleviate symptoms of perceived breathlessness.
This within-subject study will compare breathing comfort as well as breathing discomfort, prior, during, and after a VR intervention that provides embodied visual feedback of participants' on-going respiration. Primary outcomes include subjective reports from participants (breathing comfort and breathing discomfort) and the intervention's clinical feasibility. Secondary outcomes include subjective ratings on perceived embodiment and sense of agency, as well as changes in respiration rate and variability.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Covid19, Dyspnea
7. Study Design
Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Participants perform both conditions. Condition order was randomised across participants using a script prior to data collection.
Masking
ParticipantCare Provider
Masking Description
Participants are naïve to the difference in interventions. Allocation was concealed to the care provider screening participants.
Allocation
Randomized
Enrollment
26 (Actual)
8. Arms, Groups, and Interventions
Arm Title
COVVR_A
Arm Type
Experimental
Arm Description
Participants in the COVVR_A arm complete the synchronous block first, followed by the asynchronous block.
Arm Title
COVVR_B
Arm Type
Experimental
Arm Description
Participants in the COVVR_B arm complete the asynchronous block first, followed by the synchronous block.
Intervention Type
Device
Intervention Name(s)
COVVR_Synch
Intervention Description
Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.
COVVR_Synch provided synchronous feedback: participants receive real-time feedback of their respiration.
Intervention Type
Device
Intervention Name(s)
COVVR_Asynch
Intervention Description
Participants wear a respiration belt (Vernier, Go Direct) that continuously transmits thoracic circumference readings to a mobile phone (Samsung Galaxy S8) in real-time. The mobile device is placed in a headset (Zeiss VR ONEPLUS) and used to create a stereoscopic, immersive scene in Virtual Reality. The data from the respiration belt is used to map the on-going respiration pattern onto a virtual body in the scene in one of two feedback conditions.
COVVR_Asynch provided asynchronous feedback: participants receive asynchronous, frequency modulated feedback of their respiration.
Primary Outcome Measure Information:
Title
Efficacy (Breathing Comfort & Discomfort)
Description
Efficacy will be evaluated based on subjective feedback by the patients regarding their breathing comfort and discomfort, depending on the intervention.
Subjective ratings will be measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree.
Comfort item: "My breathing was enjoyable" Discomfort item: "I had difficulty breathing"
Time Frame
through study completion, an average of one year
Title
VR Intervention Feasibility
Description
Feasibility will be evaluated using a feedback questionnaire, alongside open feedback. Agreement with the questionnaire items indicates better feasibility, acceptance, and perceived outcome.
Ratings will be measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree.
Satisfaction: Did you enjoy the VR experience? Rehabilitation: Would you like to continue using the device during your recovery? Hospital Use: Would you have liked to use this earlier during your stay at the hospital? Home Use: Would you like to continue using the device at home? Respiratory benefit: Do you think the VR feedback improved your breathing? Well-being benefit: Did the VR feedback make you feel better?
Time Frame
through study completion, an average of one year
Secondary Outcome Measure Information:
Title
Embodiment
Description
Change in subjective ratings about embodiment depending on VR intervention. Two control items are included that are not expected to change between conditions.
Ratings will be measured using a 7-point Likert scale with -3 = Strongly disagree, -2 = Disagree; -1 = Somewhat disagree; 0 = Neither agree nor disagree; 1 = Somewhat agree; 2 = Agree; 3= Strongly agree.
Breathing awareness: It seemed as if the flashing was my respiration Control 1: It seemed as if I had three bodies Breathing agency: I felt as if the virtual body was breathing with me Control 2: I felt as if the virtual body was drifting with the flashing
Time Frame
through study completion, an average of one year
Title
Respiratory Rate
Description
Change in respiratory rate depending on VR intervention. Respiratory rate (RR) will be measured in breaths per minute. RR will be assessed with respect to baseline recordings.
Time Frame
through study completion, an average of one year
Title
Respiratory Rate Variability
Description
Change in respiratory rate variability depending on VR intervention. Respiratory rate variability (RRV) will be measured using inter-breath intervals (IBI).
RRV will be assessed with respect to baseline recordings.
Time Frame
through study completion, an average of one year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Recovering from COVID-19 pneumonia confirmed by RT-PCR for SARS-CoV-2
Presented with persistent dyspnea with a self-rated intensity of five or higher (out of ten) on a visual analog dyspnea scale. ( "Do you have difficulty breathing?" "On a scale of 0 to 10, with 0 being no difficulty to breathe and 10 being the worst difficulty to breathe that you can imagine, where do you rank?".) This dyspnea rating will only used as an inclusion criterion and not as an outcome.
Being able to give consent
Being able to understand and speak French or English
Exclusion Criteria:
Any unstable respiratory, neurological, and cardiac conditions
Any psychiatric illness
Montreal Cognitive Assessment (MoCA) score below 25.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Olaf Blanke, Prof
Organizational Affiliation
Ecole Polytechnique Fédérale de Lausanne
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hopitaux Universitaires de Geneve (HUG)
City
Geneva
ZIP/Postal Code
1205
Country
Switzerland
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Virtual Reality Intervention Alleviates Dyspnea in Patients Recovering From COVID Pneumonia
We'll reach out to this number within 24 hrs